European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43919443" target="_blank" >RIV/00216208:11120/20:43919443 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.ejca.2019.11.015" target="_blank" >https://doi.org/10.1016/j.ejca.2019.11.015</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejca.2019.11.015" target="_blank" >10.1016/j.ejca.2019.11.015</a>
Alternative languages
Result language
angličtina
Original language name
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019
Original language description
A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumour thickness >=1.0 mm or >=0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies in stage III/IV patients are primarily anti-PD-1, independent of mutational status, or dabrafenib plus trametinib for BRAF-mutant patients. In distant metastasis, either resected or not, systemic treatment is indicated. For first-line treatment, particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma and a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harbouring a BRAF-V600 E/K mutation, this therapy shall be offered in second-line. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Cancer
ISSN
0959-8049
e-ISSN
—
Volume of the periodical
126
Issue of the periodical within the volume
February
Country of publishing house
GB - UNITED KINGDOM
Number of pages
19
Pages from-to
159-177
UT code for WoS article
000510619200019
EID of the result in the Scopus database
2-s2.0-85077148233